Testing istaroxime for severe heart failure with low blood pressure
Part of Heart & circulation clinical trials.
This trial tests a medication called istaroxime to help patients with acute heart failure and very low blood pressure (cardiogenic shock). The goal is to see if it can improve heart function and help patients recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years old
- Diagnosed with cardiogenic shock (severe heart failure with dangerously low blood pressure) from acute heart failure
- Admitted to hospital within 20 hours before joining the trial
- History of weakened heart function (ejection fraction below 40%) in the last 6 months
- Currently showing symptoms of heart failure at rest or with minimal activity
- Specific blood test results showing elevated heart-stress markers (NT-proBNP or BNP)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial studies whether doctors can safely reduce heart and blood-pressure support sooner in people with severe heart failure “shock.” It may help avoid side effects of strong medicines/devices while keeping the body’s organs well supported.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This trial is testing a temporary heart pump device that helps your heart pump blood when it's too weak to do its job. It's for people who have severe heart failure (cardiogenic shock) despite getting powerful medications to keep their heart working.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
This trial studies whether a special synchronized “heart support” treatment is safer and works better for people in cardiogenic shock. It aims to improve blood flow to organs when the heart can’t pump enough.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.